全文获取类型
收费全文 | 462519篇 |
免费 | 42754篇 |
国内免费 | 31027篇 |
专业分类
耳鼻咽喉 | 4289篇 |
儿科学 | 4865篇 |
妇产科学 | 6839篇 |
基础医学 | 56408篇 |
口腔科学 | 8182篇 |
临床医学 | 63032篇 |
内科学 | 68192篇 |
皮肤病学 | 4820篇 |
神经病学 | 25280篇 |
特种医学 | 17012篇 |
外国民族医学 | 277篇 |
外科学 | 47233篇 |
综合类 | 73882篇 |
现状与发展 | 102篇 |
一般理论 | 41篇 |
预防医学 | 28854篇 |
眼科学 | 13226篇 |
药学 | 48351篇 |
466篇 | |
中国医学 | 26431篇 |
肿瘤学 | 38518篇 |
出版年
2024年 | 1219篇 |
2023年 | 6257篇 |
2022年 | 15776篇 |
2021年 | 22874篇 |
2020年 | 17091篇 |
2019年 | 15213篇 |
2018年 | 16098篇 |
2017年 | 14448篇 |
2016年 | 13549篇 |
2015年 | 20763篇 |
2014年 | 25584篇 |
2013年 | 22886篇 |
2012年 | 33917篇 |
2011年 | 37757篇 |
2010年 | 23814篇 |
2009年 | 18429篇 |
2008年 | 25082篇 |
2007年 | 24729篇 |
2006年 | 24455篇 |
2005年 | 23991篇 |
2004年 | 15313篇 |
2003年 | 14045篇 |
2002年 | 11970篇 |
2001年 | 10591篇 |
2000年 | 11499篇 |
1999年 | 12271篇 |
1998年 | 7325篇 |
1997年 | 7384篇 |
1996年 | 5844篇 |
1995年 | 5396篇 |
1994年 | 4507篇 |
1993年 | 2863篇 |
1992年 | 3946篇 |
1991年 | 3373篇 |
1990年 | 2905篇 |
1989年 | 2592篇 |
1988年 | 2230篇 |
1987年 | 1846篇 |
1986年 | 1489篇 |
1985年 | 1260篇 |
1984年 | 697篇 |
1983年 | 521篇 |
1982年 | 323篇 |
1981年 | 348篇 |
1980年 | 261篇 |
1979年 | 320篇 |
1978年 | 132篇 |
1977年 | 140篇 |
1974年 | 144篇 |
1973年 | 111篇 |
排序方式: 共有10000条查询结果,搜索用时 375 毫秒
91.
92.
93.
Assessment of Myocardial Infarct Size by Three‐Dimensional and Two‐Dimensional Speckle Tracking Echocardiography: A Comparative Study to Single Photon Emission Computed Tomography
下载免费PDF全文
![点击此处可从《Echocardiography (Mount Kisco, N.Y.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
94.
Xiujuan Tian Zhiying Chen Shaomin Shi Xianwen Wang Wanli Wang Ning Li Jing Wang 《Medicine》2015,94(37)
Oral cancer, predominantly oral squamous cell carcinoma (OSCC), is one of the most leading causes of cancers worldwide. Due to a low 5-year survival rate, highly effective methods for the early detection of OSCC are totally needed. MicroRNAs (miRNAs), as promising biomarkers, can bring insights into tumorigenesis of oral cancers. However, studies on the accuracy of miRNAs detection in OSCC have inconsistent conclusions, leading us to conduct this meta-analysis. The aim of this study was to systematically review the articles investigating the diagnostic value of miRNAs in OSCC.The PubMed, Embase, Chinese National Knowledge Infrastructure (CNKI), Web of Science were searched (updated to June 11th, 2015) to identify all articles evaluating the diagnostic yield of miRNAs for OSCC. The pooled sensitivity, specificity, and other diagnostic parameters were used to assess the performance of miRNAs assays on OSCC detection. Statistical analysis was conducted by employing the R software.The present meta-analysis comprised 23 studies from 10 articles, including 598 OSCC patients and 320 healthy individuals, available for analysis. The summary receiver operator characteristic (SROC) curve was plotted. Meanwhile, the pooled diagnostic parameters and the area under curve (AUC) were calculated based on all included studies. The pooled diagnostic parameters calculated from all 23 studies were as follows: pooled sensitivity of 0.759 (95% CI: 0.701–0.809), pooled specificity of 0.773 (95% CI: 0.713–0.823) and AUC of 0.832, which indicates a relatively high diagnostic accuracy of miRNAs in differentiating OSCC patients from healthy controls. Meanwhile, In addition, subgroup analyses were conducted to access the heterogeneity between studies, which is based on specimen (serum/plasma/blood/saliva/ tissue) and ethnicity (Asian/Caucasian).In summary, our meta-analysis suggests that miRNAs might be used in noninvasive screening tests for OSCC, which needs further large-scale studies to be validated. 相似文献
95.
96.
Qiaojie Wang Karan Goswami Noam Shohat Arash Aalirezaie Jorge Manrique Javad Parvizi 《The Journal of arthroplasty》2019,34(5):947-953
Background
Whether prolonged operative time is an independent risk factor for subsequent surgical site infection (SSI) and periprosthetic joint infection (PJI) following total joint arthroplasty (TJA) remains a clinically significant and underexplored issue. The aim of this study is to investigate the association between operative time and the risk of subsequent SSI and PJI in patients undergoing primary TJA.Methods
We retrospectively reviewed 17,342 primary unilateral total knee arthroplasty and total hip arthroplasty performed at a single institution between 2005 and 2016, with a minimum follow-up of 1 year. A multivariate logistic regression model was conducted to identify the association between operative time and the development of SSI within 90 days and PJI within 1 year.Results
Overall, the incidence of 90-day SSI and 1-year PJI was 1.2% and 0.8%, respectively. Patients with an operative time of >90 minutes had a significantly higher incidence of SSI and PJI (2.1% and 1.4%, respectively) compared to cases lasting between 60 and 90 minutes (1.1% and 0.7%), and those lasting ≤60 minutes (0.9% and 0.7%, P < .01). In the multivariate model, the risk for infection increased by an odds ratio of 1.346 (95% confidential interval 1.114-1.627) for 90-day SSI and 1.253 (95% confidential interval 1.060-1.481) for 1-year PJI for each 20-minute increase in operative time.Conclusion
In patients undergoing primary TJA, each 20-minute increase in operative time was associated with nearly a 25% increased risk of subsequent PJI. We advocate that surgeons pay close attention to this underappreciated risk factor while maintaining safe operative practices, which minimize unnecessary steps and wasted time in the operating room. 相似文献97.
98.
Chih-Wei Hsu Sheng-Yu Lee Yao-Hsu Yang Liang-Jen Wang 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2020,23(10):653
BackgroundGeneric antidepressants are approved on the market based on evidence of bioequivalence to their brand-name versions. We aimed to assess whether generic antidepressants exert equal effectiveness as their brand-name counterparts for treating patients with depressive disorders.MethodsIn a nationwide, population-based cohort in Taiwan from 1997 through 2013, patients with a diagnosis of a depressive disorder aged between 18 and 65 years who were new users of antidepressant drugs were classified into either the brand-name group or the generic group. All patients were followed up until medication discontinuation or the end of the study period. We assessed the risk for hospitalization as a primary outcome and augmentation therapy, daily dose, medication discontinuation, or switching to another antidepressant as secondary outcomes.ResultsA total of 277 651 brand-name users (35.8% male; mean age: 41.2 years) and 270 583 generic users (35.8% male; mean age: 41.0 years) were divided into 10 different antidepressant groups (fluoxetine, sertraline, paroxetine, escitalopram, citalopram, venlafaxine, mirtazapine, moclobemide, imipramine, and bupropion). We found that patients treated with the generic form of sertraline, paroxetine, escitalopram, venlafaxine, mirtazapine, and bupropion demonstrated significantly higher risks of psychiatric hospitalization (adjusted hazard ratios ranged from 1.20–2.34), compared to their brand-name counterparts. The differences between brand-name antidepressants and their generic counterparts in secondary outcomes varied across different drugs.ConclusionsCompared to most generic antidepressants, brand-name drugs exhibited more protective effects on psychiatric hospitalization for depressive patients. These findings could serve as an important reference for clinicians when encountering patients with depressive disorder. 相似文献
99.
Richard Kim Elaine Tan Emily Wang Amit Mahipal Dung-Tsa Chen Biwei Cao Fadzai Masawi Cindy Machado James Yu Dae Won Kim 《The oncologist》2020,25(12):e1893-e1899
Lessons Learned
- The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy.
- Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily.
- The limited anticancer activity observed in this unselected patient population does not support further exploration of trametinib plus sorafenib in patients with hepatocellular carcinoma.
100.
赵阳 《中国继续医学教育》2020,(4):142-144
目的分析米非司酮和宫瘤消胶囊的联合应用对子宫肌瘤的临床治疗效果。方法本研究对象为80例子宫肌瘤患者,收治时间均在2017年3月—2018年3月期间。将上述子宫肌瘤患者随机分成两组,各40例。给予对照组患者口服米非司酮进行治疗,研究组患者在上述治疗的基础上增加宫瘤消胶囊口服治疗,记录2组患者治疗效果,性激素水平及子宫体积及肿瘤体积变化。结果(1)研究组患者的总体有效率显著高于对照组;(2)研究组患者的P、E2、LH及FSH均显著低于对照组;(3)研究组患者子宫体积及肿瘤体积均显著低于对照组。结论米非司酮片和宫瘤消胶囊的联合治疗对子宫肌瘤患者的治疗效果较显著。 相似文献